Text version
Next, let’s look at a new study of long-term benefits of brexpiprazole in major depressive disorder.
Brexpiprazole is one of the newer agents. It’s been described as a serotonin-dopamine activity modulator. In other words, it’s a partial agonist at serotonin and dopamine receptors and an antagonist at another serotonin receptor. If you’re like me, I’ve never actually managed to nail these things down, but here we go. It’s agonist at the serotonin 5-HT1A and the dopamine D2 receptor, that’s a partial agonist, and then an antagonist at the 5-HT2A. And good for you if you’ve managed to commit those to memory in terms of what their relative actions are! For brexpiprazole, there is even some action at the noradrenaline 1-alpha receptor. That’s antagonism at the noradrenaline receptor.
Now, having marched through the mechanics, you’ll remember that in the United States, brexpiprazole has an indication for schizophrenia but also for major
Unlock this Quick Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.
Already have an account? Sign in
